Quantum Genesis AI Corp. (OTC: QGAI) has released a statement addressing the Caveat Emptor designation placed on its securities by OTC Markets Group on February 12, 2026. The designation, which warns investors that there may be a public interest concern associated with the company, has prompted Quantum Genesis AI to seek clarification and initiate a formal review process.
According to the company, it has made several attempts to communicate with OTC Markets to understand the basis for the designation and determine necessary steps. OTC Markets indicated the designation relates to a “public interest concern,” but has not provided further specifics. Quantum Genesis AI has requested additional clarification and intends to cooperate fully.
OTC Markets recently informed the company that it may formally request a review of the designation starting March 13, 2026. Quantum Genesis AI plans to engage at the earliest opportunity to initiate the review process. CEO Naveen Kulkarni stated, “We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation. Our objective is to obtain clarity and take any appropriate steps.”
The Caveat Emptor designation is a red flag for investors, often leading to reduced trading liquidity and negative sentiment. For Quantum Genesis AI, a company focused on artificial intelligence, computational modeling, and scientific innovation, this designation could impact its ability to attract investment and maintain shareholder confidence. The company emphasizes its commitment to transparency and intends to provide updates as more information becomes available.
Investors can monitor developments on the company’s website at www.qgaicorp.com and its OTC Markets profile at www.otcmarkets.com/stock/QGAI. The outcome of the review process will be critical in determining whether the designation is lifted, which could restore investor confidence and normal trading activity.
